Idiopathic pulmonary fibrosis (IPF) is an under-diagnosed lung disease characterized by progressive lung scarring with median survival of 3-5 years from initial diagnosis. Although the etiology of IPF is unclear, excessive extracellular matrix (ECM) deposition is a key event in disease pathogenesis. ECM -particularly collagen and fibronectin- is excessively deposited due to increased differentiation of fibroblasts into the α-SMA-expressing myofibroblasts by transforming growth factor (TGF) β1. We predict that TGFβ1 promotes fibrosis via human antigen R (HuR), an RNA binding protein whose principle function is to promote protein translation. HuR is localized in the nucleus under normal conditions, but upon translocation from the nucleus to t...
AbstractIdiopathic pulmonary fibrosis (IPF) is characterized by the progressive and ultimately fatal...
Idiopathic pulmonary fibrosis (IPF) has no effective current treatment. It is characterized by a sub...
Abstract Background Myofibroblasts are the critical effector cells in the...
La fibrose pulmonaire peut être induite par différentes agressions comme certaines chimiothérapies e...
Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive and fatal disease of unknown origin. I...
La fibrose pulmonaire idiopathique (FPI) est une maladie rare, qui constitue la forme la plus fréque...
Màster en BiofísicaIdiopath pulmonary fibrosis (IPF) is a usually fatal disease associated with hard...
Aux stades avancés, le mélanome est le cancer de la peau le plus agressif en raison de son fort pote...
International audienceIdiopathic pulmonary fibrosis (IPF) is a chronic, progressive and fatal lung d...
Fibroblasts, and their differentiation into myofibroblasts, are important in the pathology of severa...
Idiopathic pulmonary fibrosis (IPF) is an interstitial lung disease with no cure, characterized by f...
© MacKenzie et al. 2015. Recent clinical studies show that tyrosine kinase inhibitors slow the rate ...
Idiopathic pulmonary fibrosis (IPF) is a fibrotic lung disease with no effective treatment. Myofibro...
Idiopathic pulmonary fibrosis (IPF) is the most common form of interstitial pneumonia. It is charact...
Idiopathic Pulmonary Fibrosis (IPF) is a chronic, progressive and ultimately lethal disease of the l...
AbstractIdiopathic pulmonary fibrosis (IPF) is characterized by the progressive and ultimately fatal...
Idiopathic pulmonary fibrosis (IPF) has no effective current treatment. It is characterized by a sub...
Abstract Background Myofibroblasts are the critical effector cells in the...
La fibrose pulmonaire peut être induite par différentes agressions comme certaines chimiothérapies e...
Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive and fatal disease of unknown origin. I...
La fibrose pulmonaire idiopathique (FPI) est une maladie rare, qui constitue la forme la plus fréque...
Màster en BiofísicaIdiopath pulmonary fibrosis (IPF) is a usually fatal disease associated with hard...
Aux stades avancés, le mélanome est le cancer de la peau le plus agressif en raison de son fort pote...
International audienceIdiopathic pulmonary fibrosis (IPF) is a chronic, progressive and fatal lung d...
Fibroblasts, and their differentiation into myofibroblasts, are important in the pathology of severa...
Idiopathic pulmonary fibrosis (IPF) is an interstitial lung disease with no cure, characterized by f...
© MacKenzie et al. 2015. Recent clinical studies show that tyrosine kinase inhibitors slow the rate ...
Idiopathic pulmonary fibrosis (IPF) is a fibrotic lung disease with no effective treatment. Myofibro...
Idiopathic pulmonary fibrosis (IPF) is the most common form of interstitial pneumonia. It is charact...
Idiopathic Pulmonary Fibrosis (IPF) is a chronic, progressive and ultimately lethal disease of the l...
AbstractIdiopathic pulmonary fibrosis (IPF) is characterized by the progressive and ultimately fatal...
Idiopathic pulmonary fibrosis (IPF) has no effective current treatment. It is characterized by a sub...
Abstract Background Myofibroblasts are the critical effector cells in the...